drugset / Trial / NCT01368315

CT 327 in the "Atopy Patch Test" Model

NCT01368315

Phase 1 Withdrawn 20 enrolled Creabilis SA
RandomizedSingle-groupQuadruple-blindBasic science

Summary

A Randomized, Double-Blind, Phase I, Single-Center Study on the Efficacy and Safety of CT 327 in the Atopy Patch Test model.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject CT327 Unknown 0.5 g Topical

Indications